• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere by Buckley.

作者信息

Potere Nicola, Di Nisio Marcello, Cibelli Donatella, Scurti Rosa, Frattari Antonella, Porreca Ettore, Abbate Antonio, Parruti Giustino

机构信息

Department of Medical, Oral and Biotechnological Sciences, Università degli Studi Gabriele d'Annunzio, Chieti, Italy.

VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

出版信息

Ann Rheum Dis. 2022 Oct;81(10):e195. doi: 10.1136/annrheumdis-2020-218715. Epub 2020 Sep 1.

DOI:10.1136/annrheumdis-2020-218715
PMID:32873552
Abstract
摘要

相似文献

1
Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere by Buckley.
Ann Rheum Dis. 2022 Oct;81(10):e195. doi: 10.1136/annrheumdis-2020-218715. Epub 2020 Sep 1.
2
Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere .关于Potere的“皮下注射托珠单抗阻断白细胞介素-6受体治疗重症新型冠状病毒肺炎和炎症反应过度：一项病例对照研究”的通信
Ann Rheum Dis. 2022 Oct;81(10):e194. doi: 10.1136/annrheumdis-2020-218693. Epub 2020 Sep 1.
3
Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre ' by Cheng and Zhang.
Ann Rheum Dis. 2022 Oct;81(10):e197. doi: 10.1136/annrheumdis-2020-218724. Epub 2020 Aug 19.
4
Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre .关于Della-Torre的“用萨瑞鲁单抗阻断白细胞介素-6治疗伴有全身炎症反应的重症COVID-19肺炎——一项开放标签队列研究”的通信
Ann Rheum Dis. 2022 Oct;81(10):e196. doi: 10.1136/annrheumdis-2020-218616. Epub 2020 Aug 19.
5
Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case-control study'.关于“皮下注射托珠单抗阻断白细胞介素-6受体治疗重症新型冠状病毒肺炎和炎症反应过度：病例对照研究”的通信
Ann Rheum Dis. 2023 Aug;82(8):e182. doi: 10.1136/annrheumdis-2020-218836. Epub 2020 Sep 21.
6
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.皮下注射托珠单抗阻断白细胞介素-6受体治疗重症新型冠状病毒肺炎及炎症风暴：一项病例对照研究
Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9.
7
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.白细胞介素-6 受体阻滞剂托珠单抗皮下注射可改善 COVID-19 患者的凝血活性。
Eur J Intern Med. 2021 Jan;83:34-38. doi: 10.1016/j.ejim.2020.10.020. Epub 2020 Nov 3.
8
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M by Andreica and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin .COVID-19全球风湿病联盟注册研究、抗白细胞介素-6治疗、共同决策与患者预后。对以下文章的回应：吉安弗朗切斯科撰写的“风湿病患者COVID-19住院相关特征：来自COVID-19全球风湿病联盟医生报告注册研究的数据”；汗撰写的“在临床试验出现之前，在严重COVID-19伴高炎症中同情使用托珠单抗——一家地区综合医院的真实世界经验”；安德烈伊卡撰写的“对吉安弗朗切斯科·M撰写的‘风湿病患者COVID-19住院相关特征：来自COVID-19全球风湿病联盟医生报告注册研究的数据’的评论”；安萨林撰写的“接受免疫调节药物治疗的系统性自身免疫疾病患者的COVID-19结局” 。
Ann Rheum Dis. 2022 Oct;81(10):e191. doi: 10.1136/annrheumdis-2020-218713. Epub 2020 Aug 12.
9
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.阿那白滞素治疗单独使用皮质类固醇激素或托珠单抗治疗重症 COVID-19 肺炎和中度炎症过度患者。一项回顾性队列研究。
Intern Emerg Med. 2021 Jun;16(4):843-852. doi: 10.1007/s11739-020-02600-z. Epub 2021 Jan 5.
10
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience.关于吉安弗兰切斯科的《风湿性疾病患者新冠病毒肺炎住院相关特征：来自新冠病毒肺炎全球风湿病联盟医生报告登记处的数据》的通信。在临床试验出现之前，托珠单抗在伴有高度炎症的重症新冠病毒肺炎中的同情用药——一家地区综合医院的真实世界经验。
Ann Rheum Dis. 2022 Oct;81(10):e188. doi: 10.1136/annrheumdis-2020-218528. Epub 2020 Jul 30.

引用本文的文献

1
Immune modulation: the key to combat SARS-CoV-2 induced myocardial injury.免疫调节：对抗SARS-CoV-2诱导的心肌损伤的关键。
Front Immunol. 2025 May 14;16:1561946. doi: 10.3389/fimmu.2025.1561946. eCollection 2025.
2
Targeting the NLRP3 inflammasome in cardiovascular diseases.针对心血管疾病中的 NLRP3 炎性小体。
Pharmacol Ther. 2022 Aug;236:108053. doi: 10.1016/j.pharmthera.2021.108053. Epub 2021 Dec 11.